Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Molecular Research on Bladder Cancer 2.0
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Molecular Research on Bladder Cancer 2.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (26 February 2024) | Viewed by 3845

Special Issue Editors

Prof. Dr. Thorsten Ecke
*
E-Mail Website
Guest Editor
1. Helios Hospital Bad Saarow, Bad Saarow, Germany
2. Charité-Universitätsmedizin Berlin, Berlin, Germany
Interests: bladder cancer; tumor markers; prostate cancer
* Prof. Dr. med.
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Thomas Otto

E-Mail Website
Guest Editor
Department of Urology, Lukas Hospital Neuss, D-41464 Neuss, Germany
Interests: endourology; bladder cancer; urologic oncology; molecular biology
Special Issues, Collections and Topics in MDPI journals
Dr. Florence L. Le-Calvez Kelm

E-Mail Website
Guest Editor
Department of Urology, Rheinland Klinikum Neuss, 41464 Neuss, Germany
Interests: cancer genomics; circulating genomic biomarker
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Bladder cancer is the most common cancer of the urinary tract and ranks fifth among cancers in men in Western countries. The early diagnosis of bladder cancer is mainly based on cystoscopy after gross hematuria. Based on urine or urinary cells, only a few molecular markers have been approved by the Federal Food and Drug Administration (FDA) so far. Urine soluble markers should be able to ensure a primary diagnosis, follow-up control, and screening of high-risk populations. In addition, these markers are designated merely as supporting tools for monitoring bladder cancer patients instead of replacing cystoscopy. New biomarkers in serum and urine, including nucleic acid or protein-based tissue biomarkers, have been described. However, not only the diagnosis but also the molecular research on this very common disease is important to obtain. In Arthur Rimbaud’s words, the vision of new scientific reports should be illuminated in this series of Special Issues with “Molecular Research on Bladder Cancer”. 

We warmly welcome submissions, including original papers and reviews, on this widely discussed topic.

Prof. Dr. Thorsten Ecke
Prof. Dr. Thomas Otto
Dr. Florence L. Le-Calvez Kelm
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • urinary biomarkers on bladder cancer
  • serum/plasma biomarkers
  • tissue biomarkers (nucleic acid/protein-based)
  • epigenetic markers
  • multivariate models
 

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

9 pages, 415 KiB  
Communication
Plasma Levels of Pentraxin 3: A Potential Prognostic Biomarker in Urinary Bladder Cancer Patients
by Anders Vikerfors, Sabina Davidsson, Jessica Carlsson and Tomas Jerlström
Int. J. Mol. Sci. 2024, 25(6), 3473; https://doi.org/10.3390/ijms25063473 - 20 Mar 2024
Viewed by 508
Abstract
Urinary bladder cancer (BC) represents a major health issue, and identifying novel biomarkers for early disease detection and outcome prediction is paramount. It has already been established that the immune system plays a role in tumour initiation and progression in which the inflammatory [...] Read more.
Urinary bladder cancer (BC) represents a major health issue, and identifying novel biomarkers for early disease detection and outcome prediction is paramount. It has already been established that the immune system plays a role in tumour initiation and progression in which the inflammatory marker pentraxin 3 (PTX3) might be involved, presenting a variety of functions in different cancers. The aim of this study was to investigate whether plasma levels of PTX3 could be used as a biomarker for patients with BC. Plasma levels of PTX3 were determined in 118 BC patients and 50 controls by ELISA. Patients with BC had significantly higher PTX3 levels compared to controls. The value as a diagnostic biomarker is probably limited, however, since no significant difference in PTX3 levels was seen between patients with non-muscle-invasive BC and controls; they were seen only between patients with muscle-invasive disease and controls. However, the potential value of PTX3 as a prognostic biomarker was indicated by significantly higher PTX3 levels in patients who developed metastatic disease during follow-up compared to patients who did not develop metastatic disease. The conclusions from this study are that plasma levels of PTX3 have limited value as a diagnostic biomarker, although they have potential as a prognostic biomarker for patients with BC. Full article
(This article belongs to the Special Issue Molecular Research on Bladder Cancer 2.0)
►▼ Show Figures

Figure 1

10 pages, 612 KiB  
Article
The Tumor Necrosis Factor-α Level in Platelet-Rich Plasma Might Be Associated with Treatment Outcome in Patients with Interstitial Cystitis/Bladder Pain Syndrome or Recurrent Urinary Tract Infection
by Jia-Fong Jhang, Yuan-Hong Jiang, Teng-Yi Lin and Hann-Chorng Kuo
Int. J. Mol. Sci. 2024, 25(1), 163; https://doi.org/10.3390/ijms25010163 - 21 Dec 2023
Viewed by 656
Abstract
Using platelet-rich plasma (PRP) injections to treat urological diseases has attracted great attention. This study investigated the impact of cytokine concentrations in PRP on the treatment outcome of patients with recurrent urinary tract infection (rUTI) and interstitial cystitis/bladder pain syndrome (IC/BPS). Forty patients [...] Read more.
Using platelet-rich plasma (PRP) injections to treat urological diseases has attracted great attention. This study investigated the impact of cytokine concentrations in PRP on the treatment outcome of patients with recurrent urinary tract infection (rUTI) and interstitial cystitis/bladder pain syndrome (IC/BPS). Forty patients with IC/BPS and twenty-one patients with rUTI were enrolled for four-monthly repeated PRP injections. PRP was collected at the first injection and analyzed with multiplex immunoassays for 12 target cytokines. In patients with IC/BPS, a Global Response Assessment (GRA) score ≥ 2 was defined as a successful outcome. In rUTI patients, ≤2 episodes of UTI recurrence during one year of follow-up was considered a successful outcome. Nineteen (47.5%) patients with IC/BPS and eleven (52.4%) patients with rUTI had successful outcomes. The IC/BPS patients with successful outcomes had significantly lower levels of tumor necrosis factor-α (TNF-α) in their PRP than those with unsuccessful outcomes (p = 0.041). The rUTI patients with successful outcomes also had a lower level of TNF-α (p = 0.025) and a higher level of epidermal growth factor (p = 0.035) and transforming growth factor-β2 (p = 0.024) in PRP than those with unsuccessful outcomes. A lower level of TNF-α in PRP might be a potentially predictive factor of treatment outcome. Full article
(This article belongs to the Special Issue Molecular Research on Bladder Cancer 2.0)
►▼ Show Figures

Figure 1

10 pages, 1373 KiB  
Article
Expression of S100A16 Is Associated with Biological Aggressiveness and Poor Prognosis in Patients with Bladder Cancer Who Underwent Radical Cystectomy
by Hiroki Katsumata, Kazumasa Matsumoto, Kengo Yanagita, Yuriko Shimizu, Shuhei Hirano, Kazuki Kitajima, Dai Koguchi, Masaomi Ikeda, Yuichi Sato and Masatsugu Iwamura
Int. J. Mol. Sci. 2023, 24(19), 14536; https://doi.org/10.3390/ijms241914536 - 26 Sep 2023
Cited by 1 | Viewed by 1032
Abstract
S100 calcium binding protein A16 (S100A16) is expressed in various cancers; however, there are few reports on S100A16 in bladder cancer (BC). We retrospectively investigated clinical data including clinicopathological features in 121 patients with BC who underwent radical cystectomy (RC). Immunohistochemical staining was [...] Read more.
S100 calcium binding protein A16 (S100A16) is expressed in various cancers; however, there are few reports on S100A16 in bladder cancer (BC). We retrospectively investigated clinical data including clinicopathological features in 121 patients with BC who underwent radical cystectomy (RC). Immunohistochemical staining was performed to evaluate S100A16 expression in archived specimens. Cases with >5% expression and more than moderate staining intensity on cancer cells were considered positive. S100A16 expression was observed in 54 patients (44.6%). Univariate analysis showed that S100A16 expression was significantly associated with age, pT stage, recurrence, and cancer-specific death. Kaplan–Meier analyses showed that patients with S100A16 expression had shorter overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) than those without S100A16 expression. In multivariate analysis, pT stage was an independent prognostic factor for OS and lymph node metastasis for CSS and RFS. S100A16 expression may be a biomarker of a biologically aggressive phenotype and poor prognosis in patients with BC who underwent RC. The PI3k/Akt signaling pathway is probably associated with S100A16 and may be a therapeutic target. Full article
(This article belongs to the Special Issue Molecular Research on Bladder Cancer 2.0)
►▼ Show Figures

Figure 1

Review

Jump to: Research

15 pages, 1829 KiB  
Review
The Role of Longevity Assurance Homolog 2/Ceramide Synthase 2 in Bladder Cancer
by Clara Garcia-Vallicrosa, Juan M. Falcon-Perez and Felix Royo
Int. J. Mol. Sci. 2023, 24(21), 15668; https://doi.org/10.3390/ijms242115668 - 27 Oct 2023
Viewed by 1277
Abstract
The human CERS2 gene encodes a ceramide synthase enzyme, known as CERS2 (ceramide synthase 2). This protein is also known as LASS2 (LAG1 longevity assurance homolog 2) and TMSG1 (tumor metastasis-suppressor gene 1). Although previously described as a tumor suppressor for different types [...] Read more.
The human CERS2 gene encodes a ceramide synthase enzyme, known as CERS2 (ceramide synthase 2). This protein is also known as LASS2 (LAG1 longevity assurance homolog 2) and TMSG1 (tumor metastasis-suppressor gene 1). Although previously described as a tumor suppressor for different types of cancer, such as prostate or liver cancer, it has also been observed to promote tumor growth in adenocarcinoma. In this review, we focus on the influence of CERS2 in bladder cancer (BC), approaching the existing literature about its structure and activity, as well as the miRNAs regulating its expression. From a mechanistic point of view, different explanations for the role of CERS2 as an antitumor protein have been proposed, including the production of long-chain ceramides, interaction with vacuolar ATPase, and its function as inhibitor of mitochondrial fission. In addition, we reviewed the literature specifically studying the expression of this gene in both BC and biopsy-derived tumor cell lines, complementing this with an analysis of public gene expression data and its association with disease progression. We also discuss the importance of CERS2 as a biomarker and the presence of CERS2 mRNA in extracellular vesicles isolated from urine. Full article
(This article belongs to the Special Issue Molecular Research on Bladder Cancer 2.0)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop